bevacizumab biobetter antibody (PBP1503)
/ Prestige BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2021
Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizumab Biosimilar in the Russian Federation
(Businesswire)
- “Prestige BioPharma and Pharmapark…announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma's Bevacizumab biosimilar in the Russian Federation…The partnership arrangement includes the exclusive rights for Pharmapark to commercialize the Bevacizumab biosimilar in the Russian Federation, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.”
Licensing / partnership • Oncology
1 to 1
Of
1
Go to page
1